JP2021502102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502102A5 JP2021502102A5 JP2020526075A JP2020526075A JP2021502102A5 JP 2021502102 A5 JP2021502102 A5 JP 2021502102A5 JP 2020526075 A JP2020526075 A JP 2020526075A JP 2020526075 A JP2020526075 A JP 2020526075A JP 2021502102 A5 JP2021502102 A5 JP 2021502102A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- cells
- pharmaceutical composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims description 62
- 150000007523 nucleic acids Chemical group 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 24
- 150000003384 small molecules Chemical class 0.000 claims description 19
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000002194 synthesizing effect Effects 0.000 claims description 7
- 230000009261 transgenic effect Effects 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 6
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 6
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960000951 mycophenolic acid Drugs 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 108010087227 IMP Dehydrogenase Proteins 0.000 claims description 2
- 102000006674 IMP dehydrogenase Human genes 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 108700026244 Open Reading Frames Proteins 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 230000004186 co-expression Effects 0.000 claims description 2
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 229940014456 mycophenolate Drugs 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1718697.4 | 2017-11-13 | ||
| GBGB1718697.4A GB201718697D0 (en) | 2017-11-13 | 2017-11-13 | Cell |
| PCT/GB2018/053262 WO2019092442A1 (en) | 2017-11-13 | 2018-11-12 | Cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502102A JP2021502102A (ja) | 2021-01-28 |
| JP2021502102A5 true JP2021502102A5 (enExample) | 2021-10-28 |
Family
ID=60788303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526075A Withdrawn JP2021502102A (ja) | 2017-11-13 | 2018-11-12 | 細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200345776A1 (enExample) |
| EP (1) | EP3710045A1 (enExample) |
| JP (1) | JP2021502102A (enExample) |
| CN (1) | CN111344006A (enExample) |
| AU (1) | AU2018364490A1 (enExample) |
| CA (1) | CA3082265A1 (enExample) |
| GB (1) | GB201718697D0 (enExample) |
| WO (1) | WO2019092442A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020530993A (ja) * | 2017-08-02 | 2020-11-05 | オートラス リミテッド | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 |
| CN113543792A (zh) | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| US20230338532A1 (en) * | 2020-09-11 | 2023-10-26 | National University Of Singapore | Immunosuppressant drug resistant armored tcr t cells for immune-therapy of organ transplant patients |
| CN116463362B (zh) * | 2023-06-15 | 2023-09-19 | 中国中医科学院中药研究所 | 一种细胞分裂抑制剂的制备方法 |
| CN117384931B (zh) * | 2023-12-06 | 2024-03-08 | 中国中医科学院中药研究所 | 一种GSK-3β抑制剂的制备方法 |
-
2017
- 2017-11-13 GB GBGB1718697.4A patent/GB201718697D0/en not_active Ceased
-
2018
- 2018-11-12 EP EP18804094.3A patent/EP3710045A1/en not_active Withdrawn
- 2018-11-12 AU AU2018364490A patent/AU2018364490A1/en not_active Abandoned
- 2018-11-12 US US16/763,539 patent/US20200345776A1/en not_active Abandoned
- 2018-11-12 CA CA3082265A patent/CA3082265A1/en active Pending
- 2018-11-12 JP JP2020526075A patent/JP2021502102A/ja not_active Withdrawn
- 2018-11-12 CN CN201880073185.5A patent/CN111344006A/zh active Pending
- 2018-11-12 WO PCT/GB2018/053262 patent/WO2019092442A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502102A5 (enExample) | ||
| JP7745032B2 (ja) | 一本鎖および多鎖キメラポリペプチドならびにその使用方法 | |
| JP2020511115A5 (enExample) | ||
| JP6775515B2 (ja) | トランスポザーゼポリペプチド及びその使用 | |
| JP2020530280A5 (enExample) | ||
| KR20190133732A (ko) | 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주 | |
| Tian et al. | Three TNFR-binding domains of PGRN act independently in inhibition of TNFα binding and activity | |
| JP2013505713A5 (enExample) | ||
| CN109312361A (zh) | 转座子系统及应用方法 | |
| UA79235C2 (en) | Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition | |
| JP2018535207A5 (enExample) | ||
| KR20170128254A (ko) | Cd1d를 표적화하는 단일 도메인 항체 | |
| JP2022521278A (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| CN107475275A (zh) | 嵌合抗原受体及其表达基因、双抗原调节的嵌合抗原受体修饰的t细胞及其应用 | |
| CN117069844B (zh) | 包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用 | |
| CN112625137A (zh) | 一种人白细胞介素10-Fc融合蛋白及其医药用途 | |
| KR101310511B1 (ko) | 흉선-특이성 단백질 | |
| WO2007010989A1 (ja) | 神経分化誘導ペプチド及びその利用 | |
| JPWO2019236577A5 (enExample) | ||
| JP6684211B2 (ja) | Ｂ細胞集団の製造方法 | |
| JP6385732B2 (ja) | 免疫応答制御剤 | |
| US20190338001A1 (en) | Composition Containing SMAD Protein for Treatment of Autoimmune Diseases, a Fusion Protein Comprising SMAD Protein, an Expression Vector and a Method for Preparing the Same | |
| US7030222B2 (en) | Human gastric cancer antigen gene and gastric cancer antigen protein | |
| JPH02500640A (ja) | 所定のポリペプチドと糖に対して親和性のタンパク質とをコードする核酸配列を含む組換体ｄｎａにより形質転換された宿主生物中で該ポリペプチドを製造する方法。応用、特にワクチン組成物の製造への応用 | |
| CN102000323B (zh) | Sj16蛋白在制备免疫抑制药物中的应用 |